We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

54 hedge funds and large institutions have $187M invested in TScan Therapeutics in 2023 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 4

156% more capital invested

Capital invested by funds: $73.2M → $187M (+$114M)

69% more funds holding

Funds holding: 32 → 54 (+22)

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

8.16% more ownership

Funds ownership: 65.66% → 73.82% (+8.2%)

Holders
54
Holders Change
+22
Holders Change %
+68.75%
% of All Funds
0.79%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
22
Increased
13
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$961K
2
Aberdeen Group
Aberdeen Group
United Kingdom
+$916K
3
Marshall Wace
Marshall Wace
United Kingdom
+$506K
4
Millennium Management
Millennium Management
New York
+$454K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$398K

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$458K
2
LBA
Letko, Brosseau & Associates
Quebec, Canada
-$53.6K
3
BlackRock
BlackRock
New York
-$39.9K
4
Northern Trust
Northern Trust
Illinois
-$1.67K
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
1
Lynx1 Capital Management
Puerto Rico
$30.5M – – –
EC
2
EcoR1 Capital
California
$29.1M – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$22.7M -$458K -100,000 -3%
BI
4
BVF Inc
California
$17.4M – – –
BBA
5
Baker Bros. Advisors
New York
$16.2M – – –
PBM
6
Propel Bio Management
California
$12.2M +$9.55M +2,087,139 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$10.4M +$163K +35,558 +2%
BlackRock
8
BlackRock
New York
$9.75M -$39.9K -8,722 -0.5%
DMC
9
Deer Management Company
New York
$7.26M – – –
AI
10
Alphabet Inc
California
$6.28M – – –
SAM
11
Simplify Asset Management
Nevada
$6.1M – – –
DF
12
DC Funds
Virginia
$3.67M – – –
Morgan Stanley
13
Morgan Stanley
New York
$2.74M +$961K +209,959 +81%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$2.28M +$383K +83,708 +27%
Aberdeen Group
15
Aberdeen Group
United Kingdom
$1.17M +$916K +200,000 New
Stifel Financial
16
Stifel Financial
Missouri
$702K +$16K +3,500 +3%
Marshall Wace
17
Marshall Wace
United Kingdom
$645K +$506K +110,551 New
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$606K +$398K +87,033 +515%
Millennium Management
19
Millennium Management
New York
$578K +$454K +99,082 New
NW
20
NewEdge Wealth
Pennsylvania
$533K – – –
BCM
21
Bridgeway Capital Management
Texas
$515K – – –
Jane Street
22
Jane Street
New York
$488K +$383K +83,622 New
Qube Research & Technologies (QRT)
23
Qube Research & Technologies (QRT)
United Kingdom
$466K +$355K +77,579 +3,219%
Citigroup
24
Citigroup
New York
$427K +$335K +73,163 New
Northern Trust
25
Northern Trust
Illinois
$417K -$1.67K -365 -0.5%
1
2 3

TCRX Hedge Fund Activity: Q4 2023 in Review

54 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q4 2023, worth a combined $187M — up 156% from $73.2M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new TCRX positions and 0 closed out — a net gain of 22 holders — while 13 added to existing stakes and 4 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $961K. The largest seller was Adage Capital Partners, cutting an estimated $458K.

  • 54 institutional investors held TScan Therapeutics (TCRX) as of Q4 2023, up from 32 in Q3 2023.
  • Funds reported $187M of TScan Therapeutics stock for Q4 2023, up 156% quarter-over-quarter.
  • 22 funds opened new TScan Therapeutics positions in Q4 2023 and 0 closed out, a net change of +22 holders.
  • The largest TScan Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $961K added.
  • The largest TScan Therapeutics seller in Q4 2023 was Adage Capital Partners, an estimated $458K sold.

Based on aggregated 13F filings for Q4 2023.